GLP1_NEW
Semaglutide and bimagrumab 1.0 to 10 mg injection once weekly
BIMASEMA_SC_1p0-10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD 2.44 (-9.10 to 13.30) | 0.25 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 30.77 (5.38 to 265) | 0.71 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.35 (2.40 to 26.17) | 0.57 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 7.97 (2.66 to 21.42) | 0.54 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.01 (0.29 to 3.08) | 0.54 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.28 (0.65 to 7.36) | 0.45 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.92 (1.54 to 5.53) | 0.61 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.17 (0.70 to 6.43) | 0.72 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.50 (1.71 to 7.03) | 0.24 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.22 (0.41 to 3.40) | 0.68 |